Patient Information Leaflet Drug interaction with ED drug treatments

Size: px
Start display at page:

Download "Patient Information Leaflet Drug interaction with ED drug treatments"

Transcription

1 Patient Information Leaflet Drug interaction with ED drug treatments This document is intended for information purposes only and should be used in conjunction with the advice and further details to be discussed by Mr. Ahmed at your consultation meeting. Watch out for Interactions Between Drugs for Erectile Dysfunction and Other Medications Anyone with a television probably knows that three prescription medications currently are used to treat erectile dysfunction (ED): sildenafil (VIAGRA), tadalafil (CIALIS) and vardenafil (LEVITRA). These drugs, which belong to the class of drugs called phosphodiesterase 5 inhibitors (PDE5i), are widely used, especially in older men. And because older men are more likely to be concurrently taking other medications, they should be aware of the potential for dangerous interactions when ED drugs are mixed with other prescription drugs. This article deals only with these three approved prescription ED drugs, not the many untested ED products widely advertised on the Internet and elsewhere (see Tables 1, 2, and 3). How do ED drugs interact? Sildenafil, tadalafil and vardenafil are drugs that cause the dilation of blood vessels (vasodilators) and this effect can be magnified when they are used with other medications with similar vasodilating effects. It is this vasodilating effect that increases blood flow to the penis causing an erection. Most ED drug interactions, however, result from the fact that these drugs are metabolized by the enzyme CYP3A4 in the intestine and liver. CYP3A4 is the most important enzyme for drug metabolism, and many medications can interact with ED drugs by decreasing or increasing CYP3A4 activity, causing ED drug levels to increase or decrease, respectively. Interactions with vasodilators People who take nitrates (drugs commonly used to dilate the blood vessels in the heart for patients with coronary artery disease, such as nitroglycerin, also Poppers ), either on a regular schedule or as needed, should not use these ED drugs. A dangerous reduction in blood pressure may occur, potentially leading to a heart attack or stroke, and so these drugs should not be used in combination. ED drugs also can enhance the blood pressure lowering effects of alpha blockers such as doxazosin (CARDURA), prazosin (MINIPRESS), terazosin (HYTRIN), tamsulosin (FLOMAX) and alfuzosin (UROXATRAL).. These drugs are used to treat both high blood pressure and enlarge prostate glands. If you are on an alpha blocker, consult your physician before taking an ED drug; he or she may recommend dosage adjustments or other precautions. Interactions with drugs that decrease CYP3A4 activity Drugs that inhibit CYP3A4 can substantially increase plasma concentrations of ED drugs, potentially leading to toxicity. See Table 2 for a list of drugs that inhibit CYP3A4. If you are taking any of these drugs, check with your physician before taking an ED drug. Your physician may advise a dosage reduction of the ED drug, especially if you are taking a potent CYP3A4 inhibitor such as ketoconazole, itraconazole or ritonavir. Keep in mind that grapefruit juice is also a CYP3A4 inhibitor. Interactions with drugs that increase CYP3A4 activity Drugs that increase CYP3A4 activity (see Table 3) tend to reduce the effect of ED drugs. This is not dangerous, of course, but it may render the ED drug ineffective. If the increased CYP3A4 activity is marked such as in patients taking the antibiotic rifampin, even the highest Drug interaction with ED drug treatments (UH08) V1.2 Mar 2012 Page 1 of 6

2 recommended dose of the ED drug may be ineffective. Again, if you are taking any of the medications in Table 3, talk to your physician before starting an ED drug so he or she will know that the effect of the ED drug may be compromised. (See Tables 1, 2 and 3 on Page 3.) What You Can Do Many medications have the potential to interact with ED drugs, so it is important to make sure that the physician prescribing the ED drug is aware of all the other medications you are taking. If you start or stop other medications after receiving a prescription for an ED drug, check to make sure your ED drug effect will not increase or decrease as a result. Table 1. List of Drugs That May Cause Excessive Decreases in Blood Pressure When Taken with ED Drugs Isosorbide dinitrate Isosorbide mononitrate Nitroglycerin DILATRATE-SR, ISORDIL, SORBITRATE IMDUR, ISMO, MONOKET MINITRAN, NITRO-BID, NITRO-DUR, NITROSTAT, TRANSDERM- NITRO Alpha Blockers Nitrates Generic Name BRAND NAME(may be the brand name is different. Always check on the label for the generic name if not sure) Generic Name Doxazosin Prazosin BRAND NAME CARDURA MINIPRESS Terazosin HYTRIN Drug interaction with ED drug treatments (UH08) V1.2 Mar 2012 Page 2 of 6

3 Cyclosporine NEORAL, Tamsulosin FLOMAX SANDIMMUNE Alfuzosin UROXATRAL Darunavir PREZISTA Dasatinib SPRYCEL Table 2. Drugs That May Cause ED Drug Toxicity by Decreasing CYP3A4 Activity Delavirdine RESCRIPTOR Generic Name BRAND NAME Diltiazem CARDIZEM, CARDIZEM CD, DILACOR XR, TIAZAC Amprenavir AGENERASE Aprepitant EMEND Erythromycin EES, ERYTHROCIN Atazanavir REYATAZ Fluconazole DIFLUCAN Clarithromycin BIAXIN Fluvoxamine LUVOX Conivaptan VAPRISOL Drug interaction with ED drug treatments (UH08) V1.2 Mar 2012 Page 3 of 6

4 Fosamprenavir LEXIVA Posaconazole NOXAFIL Grapefruit Juice Quinupristin SYNERCID Imatinib GLEEVEC Ritonavir NORVIR Indinavir CRIXIVAN Saquinavir FORTOVASE, INVIRASE Itraconazole SPORANOX Telithromycin KETEK Ketoconazole NIZORAL Troleandomycin TAO Lapatinib TYKERB Verapamil CALAN, CALAN SR, COVERA-HS, Mifeprestone MIFEPREX ISOPTIN, ISOPTIN SR, VERELAN Nefazodone SERZONE Voriconazole VFEND Nelfinavir VIRACEPT Drug interaction with ED drug treatments (UH08) V1.2 Mar 2012 Page 4 of 6

5 Zafirlukast ACCOLATE Efavirenz SUSTIVA PLEASE DO NOT STOP ANY OF THESE Modafinil PROVIGIL DRUGS WITHOUT CONSULTING WITH YOUR DOCTOR. Nafcillin NALLPEN, UNIPEN Table 3. Drugs That May Inhibit the Effect of ED Drugs by Increasing CYP3A4 Activity Nevirapine VIRAMUNE Oxcarbazepine TRILEPTAL Generic Name BRAND NAME Phenobarbital LUMINAL, Aminoglutethimide CYTADREN SOLFOTON Bosentan TRACLEER Primidone MYSOLINE Carbamazepine CARBATROL, Phenytoin DILANTIN TEGRETOL Rifabutin MYCOBUTIN Dexamethasone DECADRON, HEXADROL, MYMETHASONE Drug interaction with ED drug treatments (UH08) V1.2 Mar 2012 Page 5 of 6

6 Rifampin RIFADIN, RIMACTANE Rifapentine PRIFTIN St. John s wort Disclaimer: This document is for information only and should not be used for the diagnosis or treatment of medical conditions. Urology and Healthcare has used all reasonable care in compiling the information but make no warranty as to its accuracy. Urology and Healthcare is the trading name of Urology and Healthcare Ltd. Drug interaction with ED drug treatments (UH08) V1.2 Mar 2012 Page 6 of 6

HELPFUL TIPS WHEN FACING CHRONIC HEPATITIS C

HELPFUL TIPS WHEN FACING CHRONIC HEPATITIS C HELPFUL TIPS WHEN FACING CHRONIC HEPATITIS C STAYING PROACTIVE DURING TREATMENT No matter how chronic hepatitis C (genotype 1) entered your life, there are things you can do to stay proactive while you

More information

CIALIS (See-AL-iss) (tadalafil) tablets

CIALIS (See-AL-iss) (tadalafil) tablets 1 Patient Information CIALIS (See-AL-iss) (tadalafil) tablets Read this important information before you start taking CIALIS and each time you get a refill. There may be new information. You may also find

More information

Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants

Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants Drug/Drug and Drug/Food Interactions with Target-Specific Oral Anticoagulants Sara R. Vazquez, PharmD, BCPS, CACP Clinical Pharmacist University of Utah Health Care Thrombosis Service Nothing to disclose

More information

862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1. Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians

862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1. Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians 862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 1 Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians 2014 862060_Rec Drug Guide.qxd 2/5/14 1:06 PM Page 2 Recreational Drugs

More information

Daclatasvir (Daklinza)

Daclatasvir (Daklinza) FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in

More information

Adherence to oral cancer therapies

Adherence to oral cancer therapies Adherence to oral cancer therapies Just take your medicine Linda Nielsen, MS, DNPc, AOCNP Hematology Oncology of Indiana, PC Importance of Adherence Study of breast cancer patients, adherence dropped from

More information

The Novel Oral Anticoagulants

The Novel Oral Anticoagulants Induction and Follow up: The Novel Oral Anticoagulants Frances Akinwunmi, Consultant Pharmacist, Anticoagulation Imperial College Healthcare NHS Trust Overview Recap on context NICE guidance Key features

More information

Erectile Dysfunction (ED)

Erectile Dysfunction (ED) Information from your Patient Aligned Care Team What is Erectile Dysfunction or ED? Erectile dysfunction (also known as impotence) is the inability to get and keep an erection firm enough for sex. Having

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet 02300699 1 tablet daily. Complera 200/25/300 mg tablet 02374129 1 tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ emtricitabine/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ emtricitabine/

More information

Interactions with COUMADIN

Interactions with COUMADIN COUMADIN INDICATIONS COUMADIN (warfarin sodium) is a prescription medicine used to treat blood clots and to lower the chance of blood clots forming in your body. Blood clots can cause a stroke, heart attack,

More information

MEDICATION GUIDE XARELTO (zah-rel-toe) (rivaroxaban) Tablets

MEDICATION GUIDE XARELTO (zah-rel-toe) (rivaroxaban) Tablets MEDICATION GUIDE XARELTO (zah-rel-toe) (rivaroxaban) Tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide

More information

Bristol-Myers Squibb and Gilead Sciences, LLC 50

Bristol-Myers Squibb and Gilead Sciences, LLC 50 Patient Information ATRIPLA (uh TRIP luh) Tablets ALERT: Find out about medicines that should NOT be taken with ATRIPLA. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA." Generic

More information

Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.c om

Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.c om News Release Media contacts: Ernie Knewitz Tel: 908.927.2953 Mobile: 917.697.2318 eknewitz@its.jnj.com Shaun Mickus Phone: 908.927.2416 Mobile: 973.476.7144 smickus@its.jnj.c om Investor contacts: Stan

More information

Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement

Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder,

More information

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Read this Patient Information carefully before you start taking VYTORIN and each time you get a refill. There may be new information.

More information

Marketplace Health Plans Template Assessment Tool October 2014

Marketplace Health Plans Template Assessment Tool October 2014 Marketplace Health Plans Template Assessment Tool October 2014 Beginning in January 2015, state and federal Marketplaces (aka exchanges) will again offer a range of insurance plans called qualified health

More information

Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cardiovascular Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cardiovascular Drugs PassAssured's Pharmacy Technician Training Program Medication Review

More information

Novel oral anticoagulants (NOACs): novel problems and their solutions

Novel oral anticoagulants (NOACs): novel problems and their solutions Novel oral anticoagulants (NOACs): novel problems and their solutions Martin H. Ellis MD Hematology Institute and Blood Bank Meir Medical Center January 2013 OVERVIEW NOACs in clinical use Review of pivotal

More information

Novel Oral Anticoagulants (NOACs) Prescriber Update 2013

Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg

More information

North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV

North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV North Carolina Marketplace Plans with More Affordable Drug Cost Sharing for People with HIV Of North Carolina s marketplace insurance offerings, only Blue Cross Blue Shield s plans are potentially affordable

More information

Trileptal (Oxcarbazepine)

Trileptal (Oxcarbazepine) Brand and Generic Names: Trileptal Tablets: 150mg, 300mg, 600mg Liquid Suspension: 300mg/5mL Generic name: oxcarbazepine What is Trileptal and what does it treat? Trileptal (Oxcarbazepine) Oxcarbazepine

More information

Os Novos Anticoagulantes não são necessários

Os Novos Anticoagulantes não são necessários Os Novos Anticoagulantes não são necessários H. Luz Rodrigues Serviço de Nefrologia e Transplantação Instituto de Farmacologia e Neurociências 1948 Introdução dum ratícida Warfarin Wisconsin Alumni Research

More information

Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment

Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment Perspective Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment Direct-acting antiviral (DAA) drugs exhibit considerable variability in mechanisms of metabolism

More information

Sudden dizziness, trouble walking, loss of balance or coordination

Sudden dizziness, trouble walking, loss of balance or coordination rivaroxaban (Xarelto) Patient Education Information Sheet Veterans Health System Pharmacy Service 119 What is rivaroxaban (Xarelto)? A new anticoagulant ( blood thinner ) that reduces the risk of stroke

More information

HIV 1. A reference guide for prescription HIV-1 medications

HIV 1. A reference guide for prescription HIV-1 medications HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants

More information

Drug Treatment Program Update

Drug Treatment Program Update Drug Treatment Program Update As of May 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions

More information

Package leaflet: Information for the user. CIALIS 20 mg film-coated tablets Tadalafil

Package leaflet: Information for the user. CIALIS 20 mg film-coated tablets Tadalafil Package leaflet: Information for the user CIALIS 20 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

Managing Drug Interactions in Transplant Recipients

Managing Drug Interactions in Transplant Recipients Managing Drug Interactions in Transplant Recipients David J. Quan, Pharm.D., BCPS Clinical Pharmacist Clinical Professor of Pharmacy Department of Pharmaceutical Services UCSF Medical Center Goals and

More information

My remarks today and the information contained in these slides do not necessarily reflect the official views of FDA.

My remarks today and the information contained in these slides do not necessarily reflect the official views of FDA. Possible Criteria that Warrant In Vivo P-Glycoprotein Glycoprotein-Mediated Drug Interaction Studies Based on In Vitro Assessment Lei Zhang, Ph.D. Office of Clinical Pharmacology Office of Translational

More information

ANTICOAGULANT DRUG INTERACTIONS. New Agents, New Concerns

ANTICOAGULANT DRUG INTERACTIONS. New Agents, New Concerns ANTICOAGULANT DRUG INTERACTIONS New Agents, New Concerns Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine

More information

News Release. Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com

News Release. Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com News Release Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com Christina Chan Tel: (908) 927-5769 Mobile: (908) 635-2406 cchan20@its.jnj.com Investor Relations

More information

Helpful HIV Medication Tables for Pharmacists

Helpful HIV Medication Tables for Pharmacists 861837_Pharmguide.qxd 2/5/14 12:55 PM Page 1 Helpful HIV Medication Tables for Pharmacists New York/New Jersey AIDS Education & Training Center (AETC) www.nynjaetc.org Winter 2014 861837_Pharmguide.qxd

More information

Novel Anticoagulants: Case of Mr. T

Novel Anticoagulants: Case of Mr. T Novel Anticoagulants: Case of Mr. T Your Orthopedic surgeon calls you from the operating room requesting advice on VTE prevention for a 45yo male with congenital hip dysplasia and a remote history of DVT,

More information

State Health Reform Impact Modeling Project Tennessee

State Health Reform Impact Modeling Project Tennessee State Health Reform Impact Modeling Project Tennessee January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Background

More information

----------------------DOSAGE FORMS AND STRENGTHS--------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION

----------------------DOSAGE FORMS AND STRENGTHS--------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLYSIO safely and effectively. See full prescribing information for OLYSIO. OLYSIO (simeprevir) capsules,

More information

Recovery of Erectile Function After Radical Prostatectomy Vanderbilt University Department of Urologic Surgery

Recovery of Erectile Function After Radical Prostatectomy Vanderbilt University Department of Urologic Surgery Recovery of Erectile Function After Radical Prostatectomy Vanderbilt University Department of Urologic Surgery Postoperative erectile dysfunction is a potential risk of surgery for prostate cancer, whether

More information

Comprehensive Case Management Reassessment

Comprehensive Case Management Reassessment Comprehensive Case Management Reassessment Reassessment Date: Date of previous Assessment/Reassessment: Name: Client ID # Address: If Reassessment early or late explain: Current HIV Status: Asymptomatic

More information

TSOAC Initiation Checklist

TSOAC Initiation Checklist Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.

More information

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal News Release Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com Pam Van Houten Tel: (908) 927-2977 Mobile: (908) 295-7367 PVanhou5@its.jnj.com Investor Relations

More information

STATE HEALTH REFORM IMPACT MODELING PROJECT. Alabama

STATE HEALTH REFORM IMPACT MODELING PROJECT. Alabama STATE HEALTH REFORM IMPACT MODELING PROJECT Alabama January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project BACKGROUND

More information

continuing education for pharmacists

continuing education for pharmacists continuing education for pharmacists New Chronic Myeloid Leukemia Drugs: Bosulif, Iclusig, and Synribo Thomas A. Gossel, R.Ph., Ph.D., Professor Emeritus, Ohio Northern University, Ada, Ohio Volume XXXI,

More information

Practical How-to: Treating Patients with New Anticoagulants case scenarios

Practical How-to: Treating Patients with New Anticoagulants case scenarios Practical How-to: Treating Patients with New Anticoagulants case scenarios Robert Barcelona, PharmD, BCPS, Matthew Eisen, MD and Lindsey Federle, PharmD, BCPS Objectives Patient Case #1 o Discuss data

More information

State Health Reform Impact Modeling Project Florida

State Health Reform Impact Modeling Project Florida State Health Reform Impact Modeling Project Florida January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Questions may

More information

Covered California s 2016 Formularies

Covered California s 2016 Formularies Covered California s 2016 Formularies An analysis of the drugs per tier in all 12 health plans that are available for treating and preventing HIV (pp 1 24) and for treating hepatitis B (pp 26 37) and hepatitis

More information

November 6, 2015. A listing of the data presentations is included below:

November 6, 2015. A listing of the data presentations is included below: November 6, 2015 Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015 The EXPLORER program

More information

CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION GENERAL RECOMMENDATIONS:

CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION GENERAL RECOMMENDATIONS: CHAPTER 2B HIV DRUG-DRUG INTERACTIONS I. INTRODUCTION II. GENERAL RECOMMENDATIONS: The practitioner should conduct a thorough medication history at each visit that includes prescription medications, over-the-counter

More information

Alpha-Blocker Patient Advisory ASCRS and AAO Information Statement

Alpha-Blocker Patient Advisory ASCRS and AAO Information Statement Alpha-Blocker Patient Advisory ASCRS and AAO Information Statement Alpha-blocker drugs and intraoperative floppy iris syndrome (IFIS), related complications in cataract surgery Recommendations The American

More information

New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO Saturday, 26 September 2015 05:17

New Global Real-World Data from Atrial Fibrillation Studies Confirm the Safety Profile of XARELTO Saturday, 26 September 2015 05:17 Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients

More information

Package leaflet: Information for the user. Norvir 100 mg film-coated tablets ritonavir

Package leaflet: Information for the user. Norvir 100 mg film-coated tablets ritonavir Package leaflet: Information for the user Norvir 100 mg film-coated tablets ritonavir Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

RIVAROXABAN. Consumer Information

RIVAROXABAN. Consumer Information RIVAROXABAN Consumer Information Rivaroxaban is a medicine that is used to increase the time it takes for blood to clot. It belongs to a class of medicines called anticoagulants, which are sometimes also

More information

Translating clinical evidence into real-world outcomes

Translating clinical evidence into real-world outcomes Annual Swiss Stroke Society Meeting 31st of January 2013 Symposium: From RE-LY to practice: Changing the attitude on stroke prevention in AF Translating clinical evidence into real-world outcomes Unité

More information

Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis December 7, 2015 Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis XALIA is First Prospective Study to Confirm Benefit

More information

Statin Safety 2014 NLA Update

Statin Safety 2014 NLA Update Statin Safety 2014 NLA Update Kenneth A. Kellick, PharmD, Michael Bottorff, PharmD, Peter P. Toth, MD, PhD Disclosures: Kenneth Kellick has nothing to disclose Learning Objectives The material will allow

More information

FAST FACTS. About XARELTO (rivaroxaban) in Reducing the Risk of Stroke in Patients with Atrial Fibrillation. About AFib

FAST FACTS. About XARELTO (rivaroxaban) in Reducing the Risk of Stroke in Patients with Atrial Fibrillation. About AFib About XARELTO (rivaroxaban) in Reducing the Risk of Stroke in Patients with Atrial Fibrillation About AFib FAST FACTS t XARELTO is a once-daily, oral anticoagulant approved in the United States by the

More information

Clinically Significant Cardiovascular. Drug Interactions. April 30, 2014 Michael A Militello, PharmD, BCPS Cardiovascular Clinical Pharmacist

Clinically Significant Cardiovascular. Drug Interactions. April 30, 2014 Michael A Militello, PharmD, BCPS Cardiovascular Clinical Pharmacist Clinically Significant Cardiovascular Drug Interactions April 30, 2014 Michael A Militello, PharmD, BCPS Cardiovascular Clinical Pharmacist Introduction Drug interactions represent 3-5% of preventable

More information

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

MEDICAL THERAPY OF ED Ian Eardley

MEDICAL THERAPY OF ED Ian Eardley MEDICAL THERAPY OF ED Ian Eardley Erectile Dysfunction Plan of treatment Regardless of the aetiology of the ED, most men will benefit from oral therapy. If oral therapy fails, then more invasive options

More information

Erectile Dysfunction Agents Step Therapy Criteria

Erectile Dysfunction Agents Step Therapy Criteria ϯ ϯ ϯ A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association Erectile Dysfunction Agents Step Therapy Criteria

More information

sexual after Being prostate cancer... Manitoba Prostate Centre Visit our website at www.cancercare.mb.ca

sexual after Being prostate cancer... Manitoba Prostate Centre Visit our website at www.cancercare.mb.ca Manitoba Prostate Centre Being sexual after prostate cancer... Visit our website at www.cancercare.mb.ca This publication is supported by an unrestricted educational grant from Pfizer Canada Inc. Treatment

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada. IMBRUVICA is used to

More information

Coadministered Agent Dosage atazanavir 300 mg orally once daily

Coadministered Agent Dosage atazanavir 300 mg orally once daily HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TYBOST safely and effectively. See full prescribing information for TYBOST. TYBOST (cobicistat) tablets,

More information

B.C. HIV/AIDS Drug Treatment Program

B.C. HIV/AIDS Drug Treatment Program B.C. HIV/AIDS Drug Treatment Program Monthly Report January 215 215 BC Centre for Excellence in HIV/AIDS DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS

More information

South CarolinaJanuary 2013

South CarolinaJanuary 2013 STATE HEALTH REFORM IMPACT MODELING PROJECT South CarolinaJanuary 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project BACKGROUND

More information

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/.

More information for patients and caregivers can be accessed at http://www.xarelto-us.com/. Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -

More information

Drug-Drug Interactions with Antiretroviral Therapy. Case-Based Discussions

Drug-Drug Interactions with Antiretroviral Therapy. Case-Based Discussions Drug-Drug Interactions with Antiretroviral Therapy Case-Based Discussions Alice K. Pau, Pharm.D. Staff Scientist (Clinical) Clinical Pharmacy Specialist DCR/NIAID/NIH Learning Objectives Upon completion

More information

Summary of the risk management plan (RMP) for Cerdelga (eliglustat)

Summary of the risk management plan (RMP) for Cerdelga (eliglustat) EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to

More information

STATE HEALTH REFORM IMPACT MODELING PROJECT. North Carolina

STATE HEALTH REFORM IMPACT MODELING PROJECT. North Carolina STATE HEALTH REFORM IMPACT MODELING PROJECT North Carolina December 2012 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Questions

More information

New Jersey. State Health Reform Impact Modeling Project

New Jersey. State Health Reform Impact Modeling Project State Health Reform Impact Modeling Project New Jersey January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Background

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

CICLOSPORIN. What are the aims of this leaflet?

CICLOSPORIN. What are the aims of this leaflet? CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,

More information

PATIENT JOURNAL. XARELTO CarePath. Total Hip Replacement. Useful information for before, during and after surgery

PATIENT JOURNAL. XARELTO CarePath. Total Hip Replacement. Useful information for before, during and after surgery XARELTO CarePath Total Hip Replacement PATIENT JOURNAL Useful information for before, during and after surgery Always consult your healthcare professional. www.xarelto-us.com Please read additional Important

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

News Release. Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com

News Release. Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com News Release Media Contacts: Kristina Chang Tel: (908) 927-2416 Mobile: (201) 213-4115 kchang12@its.jnj.com Christina Chan Tel: (908) 927-5769 Mobile: (908) 635-2406 cchan20@its.jnj.com Investor Relations

More information

Evaluating Drugs Used to Treat: Enlarged Prostate. Comparing Effectiveness, Safety, and Price

Evaluating Drugs Used to Treat: Enlarged Prostate. Comparing Effectiveness, Safety, and Price Evaluating Drugs Used to Treat: Enlarged Prostate Comparing Effectiveness, Safety, and Price Contents Our Recommendations........................................... 3 Welcome....................................................

More information

Treatment Information Service 1 800 HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition

Treatment Information Service 1 800 HIV 0440 HIV/AIDS. HIV and Its Treatment What You Should Know. 2nd edition HIV/AIDS Treatment Information Service 1 800 HIV 0440 HIV and Its Treatment What You Should Know 2nd edition HIV/AIDS TREATMENT INFORMATION SERVICE 2nd Edition HIV and Its Treatment: What You Should Know

More information

District of Columbia

District of Columbia STATE HEALTH REFORM IMPACT MODELING PROJECT District of Columbia January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project

More information

Maryland. State Health Reform Impact Modeling Project

Maryland. State Health Reform Impact Modeling Project State Health Reform Impact Modeling Project Maryland January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project Background

More information

Opioid Pain and Addiction Management Medications Drug. Interactions with HIV Antiretrovirals. A Drug Interaction Guide for Clinicians.

Opioid Pain and Addiction Management Medications Drug. Interactions with HIV Antiretrovirals. A Drug Interaction Guide for Clinicians. 857106_Pain Bro.qxd 6/11/13 7:49 AM Page 1 Opioid Pain and Addiction Management Medications Drug Interactions with HIV Antiretrovirals A Drug Interaction Guide for Clinicians Spring 2013 NY/NJ AIDS Education

More information

Sexual Dysfunction and DIABETES in Men

Sexual Dysfunction and DIABETES in Men Sexual Dysfunction and DIABETES in Men By: Professor M H Cummings MD FRCP, Consultant Physician Honorary Professor in Diabetes and Endocrinology Portsmouth Hospitals NHS Trust SEXUAL DYSFUNCTION AND DIABETES

More information

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered

More information

High Cholesterol and Heart Disease

High Cholesterol and Heart Disease Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents 2: Our recommendations 4: Welcome 7: Who should take a statin drug? 10: Choosing

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical

More information

Slide 1. Slide 2. Slide 3. Disclosures. Objectives DRUG INTERACTIONS WITH NEW ORAL ANTICOAGULANTS. None

Slide 1. Slide 2. Slide 3. Disclosures. Objectives DRUG INTERACTIONS WITH NEW ORAL ANTICOAGULANTS. None Slide 1 DRUG INTERACTIONS WITH NEW ORAL ANTICOAGULANTS Michelle Friedman, B.S., Pharm.D. PGY-2 Internal Medicine Pharmacy Resident Kingsbrook Jewish Medical Center Chanie Wassner, Pharm.D. PGY-2 Critical

More information

o pain, aching, or tenderness on the right o loss of appetite

o pain, aching, or tenderness on the right o loss of appetite Patient Information ODEFSEY (oh-def-see) (emtricitabine, rilpivirine and tenofovir alafenamide) tablets Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with

More information

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011 Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both

More information

WORST PILLS BEST PILLS

WORST PILLS BEST PILLS WORST PILLS BEST PILLS Health Research Group Visit Health Research Group s website at www.citizen.org/hrg/ SIDNEY M. WOLFE, M.D., EDITOR Member N E W S JULY 2001 VOL. 7, NO. 7 The Diabetes Drug Metformin

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AFINITOR safely and effectively. See full prescribing information for AFINITOR. AFINITOR (everolimus)

More information

STATE HEALTH REFORM IMPACT MODELING PROJECT. Georgia

STATE HEALTH REFORM IMPACT MODELING PROJECT. Georgia STATE HEALTH REFORM IMPACT MODELING PROJECT Georgia January 2013 Prepared by the Center for Health Law and Policy Innovation of Harvard Law School and the Treatment Access Expansion Project BACKGROUND

More information

How To Get A Tirf

How To Get A Tirf Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions b r a z j i n f e c t d i s. 2 0 1 3;1 7(2):194 204 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Review article Safety aspects of protease inhibitors for chronic hepatitis

More information

Request for Prior Authorization HEPATITIS C TREATMENTS

Request for Prior Authorization HEPATITIS C TREATMENTS IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan

More information

Contents What are side effects? Why do I need to know about side effects of HIV medications?

Contents What are side effects? Why do I need to know about side effects of HIV medications? Contents What are side effects?................................ 1 Why do I need to know about side effects of HIV medications?.................................. 2 What should I ask my doctor when he or

More information

Prior Authorization of buprenophine/naloxone (Suboxone ) or buprenorphine (Subutex )

Prior Authorization of buprenophine/naloxone (Suboxone ) or buprenorphine (Subutex ) June 2010 April 2009 Prior Authorization of buprenophine/naloxone (Suboxone ) or buprenorphine (Subutex ) Effective August 1, West Virginia Medicaid will require prior authorization for all Suboxone and

More information

See 17 for PATIENT COUNSELING INFORMATION Risk of Priapism: In the event that an erection lasts more than 4 hours, the

See 17 for PATIENT COUNSELING INFORMATION Risk of Priapism: In the event that an erection lasts more than 4 hours, the HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STAXYN safely and effectively. See full prescribing information for STAXYN. STAXYN (vardenafil hydrochloride)

More information

Amlodipine 5 and 10 mg tablets

Amlodipine 5 and 10 mg tablets Package leaflet: Information for the patient Amlodipine Apotex 5 mg tablets Amlodipine Apotex 10 mg tablets Amlodipine besilate Read all of this leaflet carefully before you start taking this medicine

More information